Phreesia Q4 Earnings Release Forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PHR?
Source: Newsfilter
- Earnings Release Date: Phreesia, Inc. is set to release its Q4 earnings on March 30, with investors closely monitoring the performance to assess the company's future growth potential.
- Earnings Per Share Expectation: Analysts anticipate earnings per share to drop to 7 cents, a significant decline from 18 cents last year, indicating challenges in the company's profitability.
- Market Reactions: Latest ratings reveal mixed opinions among analysts regarding Phreesia, with some expressing optimism about its future performance while others voice concerns over its profitability, potentially impacting investor confidence.
- Industry Context: Amid increasing competition in the healthcare technology sector, Phreesia must implement effective strategies to navigate market pressures and ensure its ongoing competitiveness in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.410
Low
24.00
Averages
29.09
High
35.00
Current: 11.410
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Financial Comparison: PHREESIA reported a Q4 adjusted EBITDA of USD 29.4 million, indicating strong financial performance.
Industry Benchmark: In contrast, the estimate for IBESE's adjusted EBITDA stands at USD 28.1 million, highlighting a competitive landscape.
See More
- Fiscal Results Announcement: PHR EESIA has announced its fiscal results for the fourth quarter of 2026.
- Performance Overview: The results provide insights into the financial performance and economic standing of the organization during this period.
See More
- Earnings Announcement Schedule: Phreesia (PHR) is set to announce its Q4 earnings on March 30 after market close, with a consensus EPS estimate of $0.32, reflecting a substantial year-over-year increase of 390.9%, indicating a significant improvement in the company's profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $126.63 million, representing a 15.5% year-over-year growth, which highlights the company's robust growth in the market and sustained customer demand, potentially boosting investor confidence.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, showcasing the company's strong performance in revenue generation, which may attract more investor interest.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates saw one upward revision and two downward adjustments, indicating a cautious market sentiment regarding the company's future performance, which could impact short-term stock price volatility.
See More
- Oversold Signal: Phreesia Inc (Ticker: PHR) saw its RSI drop to 26.0 during Tuesday's trading, indicating that its stock price, which hit a low of $7.77, has entered oversold territory, suggesting that recent heavy selling may be nearing exhaustion and providing potential buying opportunities for investors.
- Market Comparison: Compared to the current RSI of 43.5 for the S&P 500 ETF (SPY), PHR's oversold condition may attract bullish investors, particularly in a market where overall performance remains relatively strong, potentially leading to increased capital inflow.
- Price Volatility: With a 52-week low of $7.77 and a high of $32.76, PHR's current trading price of $8.38 indicates significant price fluctuations, suggesting potential for a rebound that may catch the attention of short-term traders.
- Investor Sentiment: Despite the current low stock price, investor sentiment towards PHR may turn optimistic due to the oversold signal, especially as interest in other oversold stocks rises, which could drive its stock price higher.
See More
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More








